Core Viewpoint - The approval of SYH2056 by the FDA for clinical trials in the U.S. marks a significant milestone for the company, indicating potential growth in the treatment of depression [1] Company Summary - The company, Shijiazhuang Yiling Pharmaceutical, has developed a new chemical drug, SYH2056, which is a selective 5-HT2A receptor agonist aimed at improving the condition of patients with depressive disorders [1] - SYH2056 has also received approval from the National Medical Products Administration in China to conduct clinical trials starting November 2025 [1] Product Details - SYH2056 is designed to provide rapid onset of action with lasting effects and does not carry the risk of inducing hallucinations [1] - The clinical indication for SYH2056 is specifically for the treatment of depression [1]

Core Viewpoint - The company has received approval from the U.S. Food and Drug Administration (FDA) for its Class 1 chemical drug, a selective 5-HT2A receptor agonist, to conduct clinical trials in the United States [1] Group 1 - The selective 5-HT2A receptor agonist is designed to improve the condition of patients with depressive disorders [1] - The drug shows rapid onset of action with a single dose and has a long-lasting effect without causing hallucinogenic risks [1] - The product has also been approved by the National Medical Products Administration (NMPA) of China to conduct clinical trials in China starting from November 2025 [1]